Clinical trial · Observational
Preclinical Research for Personalized TCR-T Therapy for Head and Neck Cancer
NCT05697926CI-TRIAL-00063483unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will obtain tumor samples from patients with head and neck cancers and aims to develop personalized TCR-T therapy for head and neck cancer by determining the reactive TCR clone sequences in head and neck cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Experiment
- description
- The excess tumor tissue from patients following surgical resection will be collected for further analysis.
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- Clinical prognosis
- timeFrame
- 5 year postsurgery
- description
- Observation of the clinical prognosis including overall survival, progression-free survival, event-free survival, and recurrence-free survival.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Gender is not limited, age 18-75 years old; 2. Estimated survival is greater than 3 months; 3. Newly diagnosed patients with head and neck cancer without any treatment, or patients with refractory recurrent advanced head and neck cancer for which there is no available effective treatment; 4. Patients with head and neck cancer whose tumor tissue can be surgically harvested; 5. Volunteer to join the study and sign the informed consent. Exclusion Criteria: 1. Infected or had been infected with COVID-19; 2. Active hepatitis B or C virus, HIV infection, or other uncured active infected persons; 3. Patients with head and neck cancer who had received the following treatments: The patient had a history of using PD-1 and other immune checkpoint inhibitors 8 weeks before surgery; History of chemotherapy drug use 8 weeks before surgery; A history of hormone drug use within 4 weeks before surgery; 4. Other situations that are not appropriate to be included in the clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.